DAFTAR PUSTAKA
1. Lurain JR. Gestational Trophoblastic Disease : Epidemiology pathology clinical presentation and Diagnosis of Gestational Trophoblastic Disease and Management of Hydatidiform Mole. Am J Obstet Gynecol. 2010. 531-9.
2. Deep JP, Sedhai LB, Napit J, Pariyar J. Gestational Trophoblastic Disease. Journal of Chitwan Medical College 2013;3(4):4-11.
3. Ngan HY, Kohorn EI, Cole LA, et al; FIGO Cancer Report 2012 : Trophoblastic Disease. Int J Gynecol Obstet 2003; 83(Suppl 1):175–7130-6.
4. May T, Goldstein DP, Berkowitz RS. Chemotherapy Research and Practice : Current Chemotherapeutic Management of Patient with Gestational Trophoblastic Neoplasia. Hindawi Publishing Corp.
2011. Available from :
http://www.hindawi.com/journals/cherp/2011/806256/
5. Aghajanian C. Treatment of Low-Risk Gestational Trophoblastic Neoplasia. J Clin Oncol. 2011:786-8
6. McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ, et al. Low- risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 2002;20(7):1838–44.
8. Trommel V, Massuger, L. F.; Schijf, C. P.; Ten Kate-Booij, M. J.; Sweep, F. C., and Thomas, C. M. Early Identification of Resistance to First-Line Single-Agent Methotrexate in Patients With Persistent Trophoblastic Disease. J Clin Oncol 2006;24:52-58.
9. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet 2010; 376: 717–729.
10. Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa Cet et al. Gestational Trophoblastic Disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, , Ann Oncol. 2013;Vol: 24:39-50.
11. Schmid P, Nagai Y, Agarwal R et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet 2009; 374: 48–55.
12. Shih IeM, Gestational Trophoblastic Neoplasia-Pathogenesis and Potential Therapeutic Targets. Lancet Oncol 2007; 8: 642-50.
13. Martaadisoebrata D. Buku Pedoman Pengelolaan Penyakit Trofoblas Gestasional. Jakarta : EGC, 2005 ; 7 – 42.
14. Cunningham FG, Mc Donald PC, Gant NF et al. Williams Obstetrics, 20th ed. Philadelphia : Appleton and Lange, 1997 : 948
15. Martaadisoebrata D, Wirakusumah F. Obstetri Patologi. Jakarta : EGC, 2004 ; 28 – 33.
16. Ngan S, Seckl MJ. Gestational trophoblastic neoplasia management: an update. Curr Opin Oncol 2007;19(5): 486-91.
18. Alazzam M, Tidy J, Hancock BW et al. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2009 Jan 21; (1): CD007102
19. Homesley HD, Blessing JA, Schlaerth J, Rettenmaier M, Major FJ. Rapid escalation of weekly intramuscular methotrexate for nonmetastastic gestational trophoblastic disease: a Gynecologic Oncology Group study. Gynecol Oncol 1990;39(3):305–8.
20. Lybol C, Sweep FC, Harvey R et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2012; 125: 576–9.
21. McGrath S, Short D, Harvey R et al. The management and outcome of women with post-hydatidiform mole ‘low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1). Br J Cancer 2010; 102: 810–814.
22. Chalouhi GE. Golfier F. Soignon P. et al. Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patient: efficacy and toxicity. Am J Obstet Gynecol 2009;200:643.e1-643.e6.
23. Davis EC, Hoekstra AV, Rademaker AW, Schink JC, Lurain JR. Treatment of Non-metastatic and Metastatic Low-risk Gestational Trophoblastic Neoplasia: Factors Associated with Resistance to Single-agent Methotrexate Chemotherapy. Gynecol Oncol 2012; 125: 572-5.
24. Chan KL. Huang Y. Tam KF. Tse KY. Ngan YS. Single-dose methotrexate Regimen in the treatment of lowrisk gestational trophoblastic neoplasia. Am J Obstet Gynecol 2006;195: 1282-6.
Trophoblastic Tumor Initially Treated with Single-agent Chemotherapy. Gynecol Oncol 2004; 96:616-20.
26. Robert JP, Lurain JR. Treatment of Low-risk Metastatic Gestational Tropholastic Tumors with Single-agent Chemotherapy. Gynecol Oncol 1996;174:1917-24.
27. Gillani MM. Fariba B. Behtash N. Gaemmaghami F. MoosVI as. Rezayof E. The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate. J. Cancer Res. Ther. 2013; 9:38-43.
28. Garrett AP, Garner EO, Goldstein DP, Berkowitz RS. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low risk metastatic gestational trophoblastic tumors 15 years of experience. J Reprod Med 2002;47:355-61
29. Osborn R, Gerulath A. What is the Best Regimen for Low-Risk Gestational Trophoblastic Neoplasia? A Riview. J. Reprod Med 2003. Vol 49: 8.
30. Kwon JS, Elit L, Mazurka J, Moens F, Schmuck ML. Weekly Intravenous Methotrexate with Folinic Acid for Nonmetastatic Gestational Trophoblastic Neoplasia. Gynecol Oncol 2001; 82:367-70.
31. Rajagopalan PT, Zhang Z, McCourt L, Dwyer M, Benkovic SJ, Hammes GG. Interaction of dihidrofolate reductase with Methotrexate: Ensemble and Single-molecule kinetics. Proc Natl Acad Sci Usa 2002; 99(21):13481-6.
33. Lurain JR. Elfstrand EP. Single-agent Methotrexate Chemotherapy for the treatment of nonmetastatis gestational trophoblastic tumors. Am J Obstet Gynecol 1995;172:574-9.
34. Pfeffer PE, Sebire N, Lindsay I et al. Fertility-sparing partial hysterectomy for placental-site trophoblastic tumour. Lancet Oncol 2007; 8: 744–746.
35. Rustin GJ, Newlands ES, Lutz JM et al. Combination but not single agent methotrexate chemotherapy for gestational trophoblastic tumours increases the incidence of second tumours. J Clin Oncol 1996; 14: 2769–2773.
36. N. E. van Trommel, F. C. G. J. Sweep, C. P. T. Schijf, L. F. A. G. Massuger, and C. M. G. Thomas, “Diagnosis of hydatidiform mole and persistent trophoblastic disease: Diagnosis accuracy of total human chorionic gonadotropin (hCG), free hCG α-and β-subunits, and their ratios,” European Journal of Endocrinology, vol. 153, no. 4, pp. 565–575, 2005.
37. Lybol C. Westerdijk K. Sweep FC. Ottevanger PB. Massuger LF. Thomas CM. Human chorionic gonadotropin (hCG) regression s for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and Vincristine) Chemotherapy. Ann Oncol. 2012 Nov;23(11):2903-6.
38. Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecol Oncol 2005;97(2):618–23.
